TABLES OF RULES 2002

NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS

Nucleoside and Nucleotide reserve transcriptase inhibitors Protease inhibitors

Non-Nucleoside reserve transcriptase inhibitors

  Mutations associated to resistance Mutations associated to « possible resistance »
ZDV
T215Y/F
At least 3 mutations among : M41L, D67N, K70R, L210W, T215D/C/S, K219Q/E
Q151M
Insertion at codon 69
  T215D/C/S
3TC
M184V/I
Insertion at codon 69
Q151M
ddI
L74V
At least 3 TAMs including T215Y/F
Q151M
Insertion at codon 69
K65R
ddC
No enough data to provide any recommendation No enough data to provide any recommendation
d4T
V75M/S/A/T
T215Y/F
At least 3 mutations among : M41L, D67N, K70R, L210W, T215D/C/S, K219Q/E
Q151M
Insertion at codon 69
T215D/C/S
ABC
At least 5 mutations among : M41L, D67N, L74V, M184V/I, L210W, T215Y/F
K65R and L74V and Y115F and M184V/I
Q151M
Insertion at codon 69
4 mutations among : M41L, D67N, L74V, M184V/I, L210W, T215Y/F
K65R
TDF
Insertion at codon 69
3 TAMs including M41L or L210W
K65R

TAMs = M41L, D67N, K70R, L210W, T215Y/F, K219Q/E
ZDV: zidovudine, 3TC: lamivudine, ddI: didanosine, ddC: zalcitabine, d4T: stavudine, ABC: abacavir, TDF: tenofovir